European Journal of Cancer
Volume 42, Issue 1 , Pages 50-54 , January 2006

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Received 21 July 2005 ,Accepted 12 August 2005.

References 

  1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16(3):481–488
  2. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol. 1992;10:1066–1073
  3. Logothetis CJ, Dexeus F, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumours. J Clin Oncol. 1990;8:1050–1055
  4. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumours. J Urol. 1985;133:403–407
  5. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer. 1989;64:2448–2458
  6. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–3181
  7. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Clin Oncol. 1999;17(8):2546
  8. Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumours: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–2646
  9. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077
  10. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I–II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol. 2000;18(18):3247–3255
  11. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003;2:195–206
  12. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19(9):2527–2533
  13. Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 2000;88(7):1671–1678
  14. Bamias A, Aravantinos G, Deliveliotis C. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220–228

PII: S0959-8049(05)00874-9

doi: 10.1016/j.ejca.2005.08.032

European Journal of Cancer
Volume 42, Issue 1 , Pages 50-54 , January 2006

Article Tools

* Image Usage & Resolution